SecBot SecBot
144 ·Filed Jun 3, 2026

XERS

Xeris Biopharma Holdings, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001950047-26-005565
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a de minimis proposed sale by a director. No actionable signal for traders, the filing is routine and carries no material information about company fundamentals or insider sentiment. Monitor for any larger insider sales ahead of next earnings.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.15
T+0 close · Jun 3, 2026 · via day close
Latest settled
+37.89%
T+60 · $8.48
Vs SPY
+36.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 4 $6.15entry
  2. T+1 · 6mo ago +0.49%α +3.06% · $6.18
  3. T+5 · 5mo ago +12.68%α +15.24% · $6.93
  4. T+20 · 4mo ago +34.63%α +36.01% · $8.28
  5. T+60 · 3mo ago +37.89%α +36.01% · $8.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Marla Persky filed a Form 144 notice of intent to sell 15,500 shares of XERS common stock, with an estimated aggregate market value of $93,000. The shares were acquired via restricted stock units on June 3, 2026. This is a small, routine sale by a non-executive director, the dollar value is negligible relative to the company's $1.1B market cap and represents no material insider signal.

Key Facts

  • Filer: Director Marla Persky (non-executive board member)
  • Shares to be sold: 15,500 shares of common stock
  • Estimated value: $93,000 (based on filing date price of ~$6.00/share)
  • Shares acquired via restricted stock units on June 3, 2026
  • Sale intended to be executed through Morgan Stanley Smith Barney
  • Market cap of XERS: ~$1.1B, sale represents ~0.008% of market cap
  • Recent insider activity (30d): 1 prior sell totaling $101K

Financial Impact

Proposed sale of $93,000 in stock by a director, immaterial relative to $1.1B market cap

dilution

Risk Factors

  • No material risk identified from this filing alone

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005565
Document: 0001950047-26-005565-index.html0001950047-26-005565
Document: 0001950047-26-005565.txt0001950047-26-005565

US Market Status

Market Closed · Opens in 5h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026